Institution
Cordoba University
Education•Ashburn, Virginia, United States•
About: Cordoba University is a education organization based out in Ashburn, Virginia, United States. It is known for research contribution in the topics: Catalysis & Prostate cancer. The organization has 735 authors who have published 856 publications receiving 20642 citations.
Topics: Catalysis, Prostate cancer, Bladder cancer, Cancer, Urinary bladder
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A fiducial marker system specially appropriated for camera pose estimation in applications such as augmented reality and robot localization is presented and an algorithm for generating configurable marker dictionaries following a criterion to maximize the inter-marker distance and the number of bit transitions is proposed.
1,758 citations
••
TL;DR: Recognising the potentially aggressive epithelioid angiomyolipoma and mixed epithelial and stromal tumour categories may have important implications in patients' clinical management.
782 citations
••
University of Glasgow1, University of Oxford2, University of Texas Health Science Center at San Antonio3, Novartis4, Moscow State University5, University of North Carolina at Chapel Hill6, University College Cork7, Federal University of São Paulo8, National Taiwan University9, Centre Hospitalier Universitaire de Nantes10, The Chinese University of Hong Kong11, University of Leicester12, University of California, Berkeley13, University of Bern14, Tulane University15, Royal North Shore Hospital16, Medical University of Warsaw17, Harvard University18, Istanbul University19, University of Tromsø20, University of Washington21, Alfred Hospital22, University of Toronto23, University of Cape Town24, Cordoba University25, University of Illinois at Chicago26, Lahey Hospital & Medical Center27, University Medical Center Utrecht28, Umeå University29, Dresden University of Technology30, University of Liège31, Aarhus University32, Cardiovascular Institute of the South33, University of Copenhagen34, Semmelweis University35, University of Helsinki36, Duke University37
TL;DR: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.
Abstract: BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS: In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. RESULTS: The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with placebo, did not significantly reduce the incidence of either the extended cardiovascular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.43) or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 to 1.14; P=0.85). CONCLUSIONS: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. (ClinicalTrials.gov number, NCT00097786.)
620 citations
••
TL;DR: Altered expression and/or function of innate immunity receptors and signal transduction leading to defective activation and decreased chemotaxis, phagocytosis and intracellular killing of pathogens have been described.
450 citations
••
TL;DR: Two Mixed Integer Linear Programming (MILP) approaches to generate configurable square-based fiducial marker dictionaries maximizing their inter-marker distance are proposed.
415 citations
Authors
Showing all 737 results
Name | H-index | Papers | Citations |
---|---|---|---|
Liang Cheng | 116 | 1779 | 65520 |
Manuel Tena-Sempere | 87 | 351 | 23100 |
Rodolfo Montironi | 83 | 958 | 30957 |
Rafael Luque | 80 | 693 | 28395 |
Antonio Lopez-Beltran | 69 | 731 | 19652 |
Leonor Pinilla | 63 | 179 | 13574 |
Luis Martínez-Martínez | 63 | 354 | 13988 |
Jose Lopez-Miranda | 63 | 468 | 15666 |
Raul Urrutia | 60 | 293 | 11664 |
Francisco Pérez-Jiménez | 55 | 309 | 11200 |
Carmen Galán | 54 | 228 | 8438 |
Antonio A. Romero | 51 | 348 | 9958 |
Enrique Aguilar | 51 | 180 | 11216 |
Eduardo Muñoz | 50 | 241 | 8264 |
Pablo Perez-Martinez | 50 | 298 | 9818 |